Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Signal Genetics (SGNL) Signs Second MSA with for MyPRS; Success Could Lead to Larger Phase 3s
-
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Unusual 11 Mid-Day Movers 9/22: (WPCS) (VBLT) (CANF) Higher; (WGBS) (OPHC) (TANH) Lower
-
Notable Analyst Rating Changes 9/22: (PYPL) (TSL) (ALL) Upgraded; (NTAP) (ABB) (ALSN) Downgraded
-
Pre-Open Stock Movers 09/22: (AMPE) (VBLT) (WFT) Higher; (FCX) (MRD) (HZNP) Lower (more...)
-
After Hours Stocks Movers 09/21: (VBLT) (TRXC) (CORE) Higher; (THO) (MRD) (NMFC) (more...)
-
Chardan Capital Markets Starts Vascular Biogenics Ltd (VBLT) at Buy, PT $25
-
REGENXBIO (RGNX) IPO Opens Up 38%
-
REGENXBIO (RGNX) IPO Prices In-Line at $22
-
REGENXBIO Announces Pricing of Initial Public Offering
-
REGENXBIO Announces Pricing of Initial Public Offering
-
Unusual 11 Mid-Day Movers 9/16: (ITCI) (ADEP) (XNCR) Higher; (NR) (FOLD) (SPCB) LOwer
-
Notable Analyst Rating Changes 9/16: (CST) (YNDX) (ORCL) Upgraded; (HST) (FOLD) (MRK) Downgraded
-
Chardan Capital Markets Downgrades Amicus Therapeutics (FOLD) to Neutral
-
La Jolla Pharmaceutical (LJPC) Closes 2.9M Common Stock Offering
-
La Jolla Pharmaceutical Company Closes Offering of Common Stock
-
Chardan Capital Positive on Globalstar (GSAT) Following FCC Ex Parte Filing on TLPS Demo
-
Chardan Capital Markets, LLC. Announces Hiring of Michael E. Marrus to The Special Equities Group
-
La Jolla Pharmaceutical (LJPC) Prices 2.55M Common Stock Offering at $38/Share
-
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
-
Notable 52-Week Highs and Lows 9/8: (JBLU) (NAVB) (LJPC) High; (GPRO) (YGE) (VNCE) Low
-
Unusual 11 Mid-Day Movers 9/8: (CAPN) (TE) (LJPC) Higher; (ACI) (YGE) (NOR) Lower
-
REGENXBIO (RGNX) Sees IPO Price of $17 - $19/Share
-
Chardan Capital Markets Starts Nanosphere (NSPH) at Buy
-
Chardan Capital Boosts PT on La Jolla Pharma (LJPC) to $80 Following CEO Meeting
-
Amicus (FOLD) Worth Up to $50/Sh in a Takeover, Chardan Says; Scioderm Deal Terms Suggest Future Sale
-
Notable Analyst Rating Changes 8/31: (QLGC) (TWTR) (MS) Upgraded; (RGS) (UTX) (SCCO) Downgraded
-
Chardan Trims PT on Esperion (ESPR) to $36 as Negatives Continue Increasing
-
Chardan Capital Markets Downgrades Regeneron Pharma (REGN) to Neutral
-
Streetinsider.com's Hot Lunchtime Reads 8/27: (TSLA) (RJET) (QURE) (WSM)
-
Chardan Capital Trims PT on uniQure (QURE) to $35; Notes Uncertainty of Glybera in the U.S.
-
Chardan Capital Markets Reiterates Buy on CEVA, Inc. (CEVA) Ahead of Galaxy Note 5 and S6 Edge+ Launch
-
Chardan Capital Affirms Esperion (ESPR) at 'Sell'; Bear Case Confirmed, CVOT Needed for P2 Indications
-
Chardan Capital Markets, LLC Expands Global Platform With The Appointment Of George Nikitiadis As Managing Director And Head Of The International Portfolio Team In New York
-
REGENXBIO (RGNX) Files for $100M Common Stock IPO
-
Pre-Open Stock Movers 08/17: (AVEO) (ZU) (KITE) (TSLA) Higher; (ONTX) (MU) (EL) Lower (more...)
-
UPDATE: Chardan Upgrades Avalanche Biotechnologies (AAVL) to Buy
-
YOU On Demand (YOD) has Another Impressive Quarter; Chardan Capital Affirms 'Buy' Rating
-
Unique Fabricating, Inc. Reports Second Quarter Revenues of $35.7 Million; Diluted Earnings Per Share of $0.24
-
Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002
-
Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
-
RADA Announces Closing of Public Offering of Its Ordinary Shares
-
Chardan Capital Sees Himax (HIMX) Missing Q3 Revenue Estimates; Offers Update
-
Chardan Releases Industry Report Covering PharmaCyte Biotech
-
Chardan Capital Affirms Axovant Sciences (AXON) at 'Sell'; Sees as Mispriced Following vTv Therapeutics (VTVT) IPO
-
Chardan Capital Markets, LLC Expands Equity Division With Appointment Of Jeff Sklar, Managing Director and Head Of Institutional Sales
-
Chardan Capital Markets Starts MassRoots (MSRT) at Buy; Largest Social Network for Cannabis Community
-
Chardan Capital Boosts PT on Esperion (ESPR) to $45; New Disclosure Does Not Reveal Higher Rate of SAEs for ETC-1002
-
EyeGate (EYEG) Prices $10M Offering of Common Stock and Warrants

